Antigenic diversity of Neisseria meningitidis isolated in Taiwan between 1995 and 2002

References

• Abdillahi H, Poolman JT. Neisseria meningitidis group B serosubtyping using monoclonal antibodies in whole-cell ELISA. Microb Pathog 1988; 4: 27–32
   PubMedGoogle Scholar
• Alcala B, Arreaza L, Salcedo C, Uria MJ, De La Fuente L, Vazquez JA. Capsule switching among C:2b:P1.2,5 meningococcal epidemic strains after mass immunization campaign, Spain. Emerg Infect Dis 2002; 8: 1512–4
   PubMed Web of Science ®Google Scholar
• Charalambous BM, Feavers IM. Peptide mimics elicit antibody responses against the outer-membrane lipooligosaccharide of group B Neisseria meningitidis. FEMS Microbiol Lett 2000; 191: 45–50
   PubMed Web of Science ®Google Scholar
• Claassen I, Meylis J, van der Ley P, Peeters C, Brons HJ., Robert J, et al. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine 1996; 14: 1001–8
   PubMed Web of Science ®Google Scholar
• Finne J, Bitter-Suermann D, Goridis C, Finne U. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol 1987; 138: 4402–7
   PubMed Web of Science ®Google Scholar
• Frasch CE. Development of meningococcal serotyping. Evolution of Meningococcal Disease, NA Vedros. CRC Press II, Boca Raton, Florida 1987; 39–55
   Google Scholar
• Frasch CE. Vaccine for prevention of meningococcal disease. Clin Microbiol Rev 1989; 2: S134–8
   Google Scholar
• Frasch CE. Meningococcal vaccines: past, present and future. Meningococcal Disease, K Cartwright. John Wiley and Sons, New York 1995; 245–83
   Google Scholar
• Gupta S, Maiden MC, Feavers IM, Nee S, May RM, Anderson RM. The maintenance of strain structure in populations of recombining infectious agents. Nat Med 1996; 2: 437–442
   PubMedGoogle Scholar
• Hsueh PR, Teng LJ, Lin TY, Chen KT, Hsu HM, Twu SJ, et al. Re-emergence of meningococcal disease in Taiwan: circulation of domestic clones of Neisseria meningitidis in the 2001 outbreak. Epidemiol Infect 2004; 132: 637–45
   Google Scholar
• Jodar L, Feavers IM, Salisbury D, Granoff DM. Development of vaccines against meningococcal disease. Lancet 2002; 359: 1499–508
   PubMed Web of Science ®Google Scholar
• Jones DM, Borrow R, Fox AJ, Gray S, Cartwright KA, Poolman JT. The lipooligosaccharide immunotype as a virulence determinant in Neisseria meningitidis. Microb Pathog 1992; 13: 219–24
   Google Scholar
• Mackinnon FG, Borrow R, Gorringe AR, Fox AJ, Jones DM, Robinson A. Demonstration of lipooligosaccharide immunotype and capsule as virulence factors for Neisseria meningitidis using an infant mouse intranasal infection model. Microb Pathog 1993; 15: 359–66
   PubMed Web of Science ®Google Scholar
• Mayer LW, Reeves MW, Al-Hamdan N, Sacchi CT, Taha MK, Ajello SE, et al. Outbreak of W135 meningococcal disease in 2000: not emergence of a new W135 strain but clonal expansion within the electophoretic type-37 complex. J Infect Dis 185; 2002: 1596–1605
   Google Scholar
• Peeters CC, Rumke HC, Sundermann LC, Rouppe van der Voort EM, Meulenbelt J, Schuller M, et al. Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine. Vaccine 1996; 14: 1009–15
   PubMed Web of Science ®Google Scholar
• Pollard AJ, Scheifele D. Meningococcal disease and vaccination in North America. J Paediatr Child Health 2001; 37: S20–7
   Google Scholar
• Rosenqvist E, Hoiby EA, Wedege E, Bryn K, Kolberg J, Klem A, et al. Human antibody responses to meningococcal outer membrane antigens after 3 doses of the Norwegian group B meningococcal vaccine. Infect Immun 1995; 63: 4642–52
   PubMed Web of Science ®Google Scholar
• Rosenstein NE, Fischer M, Tappero JW. Meningococcal vaccines. Infect Dis Clin North Am 2001; 15: 155–69
   PubMed Web of Science ®Google Scholar
• Rune Andersen S, Kolberg J, Hoiby EA, Namork E, Caugant DA, Oddvar L, et al. Lipopolysaccharide heterogeneity and escape mechanisms of Neisseria meningitidis: possible consequences for vaccine development. Microb Pathog 1997; 23: 139–55
   PubMedGoogle Scholar
• Russell JE, Jolley KA, Feavers IM, Maiden MC, Suker J. PorA variable regions of Neisseria meningitidis. Emerg Infect Dis 2004; 10: 674–8
   PubMed Web of Science ®Google Scholar
• Squires SG, Deeks SL, Tsang RS. Enhanced surveillance of invasive meningococcal disease in Canada: 1 January 1999 to 31 December 2001. Can Commun Dis Rep 2004; 30: 17–28
   PubMedGoogle Scholar
• Stefanelli P, Fazio C, Neri A, Sofia T, Mastrantonio P. First report of capsule replacement among electrophoretic type 37 Neisseria meningitidis strains in Italy. J Clin Microbiol 2003; 41: 5783–6
   PubMed Web of Science ®Google Scholar
• Swartley JS, Marfin AA, Edupuganti S, Liu LJ, Cieslak P, Perkins B, et al. Capsule switching of Neisseria meningitidis. Proc Natl Acad Sci 1997; 94: 271–6
   PubMed Web of Science ®Google Scholar
• Tsang RSW, Squires SG, Zollinger WD, Ashton FE. Distribution of serogroups of Neisseria meningitidis and antigenic characterization of serogroup Y meningococci in Canada, 1 January 1999 to 30 June 2001. Can J Infect Dis Med Microb 2002; 13: 391–6
   PubMedGoogle Scholar
• Tondella MC, Popovic T, Rosenstein NE, Lake DB, Carlone GM, Mayer LW, Perkins BA, and The Active Bacterial Core Surveillance Team. Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. J Clin Microbiol 2000; 38: 3323–8
   PubMed Web of Science ®Google Scholar
• Urwin R, Russell JE, Thompson EA, Holmes EC, Feavers IM, Maiden MC. Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design. Infect Immun 2004; 72: 5955–62
   PubMed Web of Science ®Google Scholar
• van der Voort ER, van Dijken H, Kuipers B, van der Biezen J, van der Ley P, Meylis J, et al. Human B- and T-cell responses after immunization with a hexavalent PorA meningococcal outer membrane vesicle vaccine. Infect Immun 1997; 65: 5184–90
   PubMed Web of Science ®Google Scholar
• Verheul AF, Snippe H, Poolman JT. Meningococcal lipopolysaccharides: virulence factor and potential vaccine component. Microbiol Rev 1993; 57: 34–49
   PubMedGoogle Scholar
• Vogel U, Claus H, Frosch M. Rapid serogroup switching in Neisseria meningitidis. N Engl J Med 2000; 342: 219–20
   PubMed Web of Science ®Google Scholar
• Wang JF, Caugant DA, Morelli G, Koumare B, Achtman M. Antigenic and epidemiologic properties of the ET-37 complex of Neisseria meningitidis. J Infect Dis 1993; 167: 1320–9
   PubMed Web of Science ®Google Scholar
• Wright JC, Williams JN, Christodoulides M, Heckels JE. Immunization with the recombinant PorB outer membrane protein induces a bactericidal immune response against Neisseria meningitidis. Infect Immun 2002; 70: 4028–34
   PubMed Web of Science ®Google Scholar
• Sacchi CT, Lemos AP, Brandt ME, Whitney AM, Melles CE, Solari CA, et al. Proposed standardization of Neisseria meningitidis PorA variable-region typing nomenclature. Clin Diagn Lab Immunol 1998; 5: 845–55
   PubMedGoogle Scholar
• Statistics of Communicable Diseases and Surveillance in Taiwan- Annual Reports 1999–2002( www.cdc.gov.tw).
   Google Scholar